• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Diabeloop, SOOIL partner on automated insulin delivery technology

June 3, 2022 By Sean Whooley

Diabeloop SOOIL dana-i insulin pump
[Images from Diabeloop and SOOIL]
Diabeloop announced today that it entered into global development and commercial agreements with insulin delivery technology developer SOOIL.

Paris-based Diabeloop, which develops therapeutic artificial intelligence (AI) applied to insulin delivery, and SOOIL will pursue and expand upon technical integration between their platforms, building on cooperation that was initiated in February 2020.

According to a news release, the companies in 2020 launched a large clinical study of 184 patients using Diabeloop’s DBLG1 i-controller and SOOIL’s Dana-i ACE pump. That study was impacted by the COVID-19 pandemic soon thereafter, but the two companies have continued with their product development since.

The partnership will pursue the technical integration of the Dana-i ACE pump within the DBLG1 system as the entry point of the collaboration.

“We are addressing a fast-moving market, asking us to make constant adaptations. Our products have received outstanding feedback from patients and doctors alike, while demonstrating fast growth across Europe,” Diabeloop CEO and co-founder Erik Huneker said in the release. “Our reinforced partnership with SOOIL Development Company is one of the ways to make our products available to patients beyond Europe. These agreements offer high-potential perspectives and a promising international collaboration for our two companies.”

The partnership aims to help the companies enter the American market with an approved automated insulin delivery solution. The companies said a clinical trial will be performed to meet the requirements of the FDA.

Diabeloop and SOOIL also intend to make the DBLG1 system with the Dana-i pump available in the European market, with obtaining CE mark approval representing the first step.

They also aim to target their home markets, with Diabeloop seeking reimbursement for the DBLG1 hybrid closed-loop system with Dana-i in France and, in Korea, Diabeloop and SOOIL will look to garner approval from the Korean FDA. The two companies also said they are considering further opportunities to expand their partnership with new innovative products and additional geographic areas of distribution.

“SOOIL Development Co Limited has the longest history – 42 years of proudly manufacturing insulin pumps, leading technology and bringing joy to people with diabetes,” SOOIL owner and founder Soo Bong Choi said. “Dana insulin pumps are intended for interoperability and this collaboration with Diabeloop will help provide people affected by diabetes more options and choice.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Research & Development, Technology Tagged With: Diabeloop, SOOIL

IN CASE YOU MISSED IT

  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS